Why do most clinical trials fail?

Because we’re only seeing part of the picture.

Traditional proteomics breaks proteins into fragments. That’s like trying to understand a sentence by reading one word at a time—out of order.

At ImmPro, we analyze whole proteoforms—the complete, functional versions of proteins—to reveal insights that fragmented data simply can’t deliver.

Introducing, ProteoSight™

The first commercial platform for single-particle, top-down proteomics.

ProteoSight™ is a precision platform built to directly detect and differentiate intact proteoforms using Individual Ion Mass Spectrometry (I2MS). Delivering unmatched clarity for drug development, diagnostics, and clinical research.

High-Mass Proteoform Resolution

Direct Single-Particle Measurements

Compatible with Challenging Samples

  • AAV Characterization

    Measure the intact mass and the percentage product filled with cargo for various AAV stereotypes.

  • Tau Profiling

    Map tau proteoforms, including pTau217, for enhanced amyloid PET prescreening in your clinical trial.

  • Custom Assays

    Design the assay that will differentiate your drug development today.

Whether you’re characterizing drug response in preclinical studies, or trying to segment your target patient population, our platform delivers clarity at every stage of development.